{"filings":[{"id":1673796,"accession_number":"0001140361-26-028604","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-07-16T11:27:30+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.","CVR milestones: $1.00 for VLS-01 Phase 3 start, $0.50 for BPL-003 US approval/DEA rescheduling, $1.00 for VLS-01 US approval/DEA rescheduling.","Termination fee of $104.3M payable by AtaiBeckley under certain conditions; no-shop with fiduciary out.","Support agreements with directors, officers, and Apeiron Investment Group to vote in favor.","Conditions include stockholder approval, HSR clearance, no MAE; expected close within 6-9 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-16","daily_digest_url":"/daily/2026-07-16","daily_digest_rank":5},{"id":920280,"accession_number":"0001140361-26-024474","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-06-08T21:00:31+00:00","items":["5.07"],"status":"ready","headline":"AtaiBeckley shareholders elect three directors, ratify Deloitte as auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sabrina Martucci Johnson, Amir Kalali, and Andrea Heslin Smiley elected as Class I directors for three-year terms.","Over 146M votes cast for each nominee; broker non-votes of ~57M shares recorded.","Ratification of Deloitte & Touche LLP as 2026 auditor approved with ~202M votes for, ~1.2M against.","Approximately 367M shares outstanding as of record date April 9, 2026; quorum of ~204M shares present.","All proposals passed as described in the April 22 definitive proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815796,"accession_number":"0001140361-26-023815","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-06-03T11:52:56+00:00","items":["7.01"],"status":"ready","headline":"AtaiBeckley to present at June 2026 conferences; will highlight BPL-003 Phase 3 initiation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jefferies Global Healthcare Conference fireside chat on June 3, 12:15 PM ET.","Oppenheimer CNS Summit on June 10 in Miami; fireside chat at 1:35 PM ET.","HCW Neuro Perspectives and UBS Virtual CNS Day both on June 15 (virtual).","Management will provide program updates, including initiation of BPL-003 Phase 3 ReConnection trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22843,"accession_number":"0001140361-26-020708","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-05-12T12:17:30+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtaiBeckley Q1 net loss $29.8M; BPL-003 Phase 3 initiation on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $209.9M as of March 31, 2026; runway into 2029.","BPL-003 Phase 3 ReConnection program (two studies, ~580 patients) to begin Q2 2026.","VLS-01 Phase 2 Elumina topline results expected in Q4 2026.","EMP-01 Phase 2a showed consistent improvements in Social Anxiety Disorder.","Appointed Michael Faerm as CFO effective March 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":954000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112563,"accession_number":"0001140361-26-008354","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AtaiBeckley enters into new ATM equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM allows AtaiBeckley to sell common stock via Jefferies as sales agent, replacing prior 2022 agreement.","Jefferies receives up to 3.0% commission on gross proceeds; no obligation to sell shares.","Proceeds to advance clinical development of product candidates and for working capital.","Sales will be made under effective S-3 registration statement filed March 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112562,"accession_number":"0001140361-26-008296","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AtaiBeckley reports pro forma combined net loss of $704M for 2025 after Beckley Psytech acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma combined net loss attributable to common stockholders $704.3M, or $3.11 per diluted share, for FY 2025.","Total combined revenues $4.1M; operating expenses $694.2M including $530M acquisition of in-process R&D.","Acquisition of Beckley Psytech closed Nov 5, 2025; 103.8 million AtaiBeckley shares issued as consideration.","Beckley Psytech historical net loss $30M for Jan 1 to Nov 5, 2025 (IFRS); pre-existing investment was 33.7%.","Acquisition accounted for as asset acquisition with no goodwill; gain recorded on previously held interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112561,"accession_number":"0001140361-26-008178","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.","Net loss $544.8M in Q4, $660M full year; includes $530M non-cash IP R&D charge from Beckley Psytech combo.","BPL-003 Phase 3 pivotal program (ReConnection-1 and -2) initiation on track for Q2 2026; topline data early 2029.","EMP-01 Phase 2a met primary safety; showed 11.85-point LSAS reduction vs placebo (p=0.036).","VLS-01 Phase 2 Elumina topline data readout anticipated H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112560,"accession_number":"0001140361-26-006880","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AtaiBeckley reports positive Phase 2a results for EMP-01 in Social Anxiety Disorder; LSAS -11.85 vs placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.","LSAS placebo-adjusted reduction of 11.85 points at Day 43 (Hedges' g=0.45, p=0.036 one-tailed).","CGI-I responders: 49% EMP-01 vs 15% placebo; NNT 2.95.","Improvements in both Fear (-13.7) and Avoidance (-15.1) subscales after two doses without psychotherapy.","71 patients enrolled, 69 completed Day 43 with high retention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112559,"accession_number":"0001140361-26-006118","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.","Faerm receives $525k base salary, 40% target bonus, option for 1.275M shares, 285k RSUs (4-yr vest), and $85k sign-on bonus.","Severance: 0.75x salary for 9 months; change-in-control: lump sum salary+target bonus plus accelerated equity vesting.","Faerm previously CFO at Viracta Therapeutics, interim CFO at Harpoon Therapeutics, and CFO at Artiva Biotherapeutics.","CEO cites Faerm's experience as BPL-003 nears Phase 3 and other clinical-stage programs advance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112558,"accession_number":"0001140361-26-000614","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.","Additional BPL-003 Phase 2a cohort evaluating two-dose induction in TRD starts Q1'26; initial data expected Q4'26.","VLS-01 (DMT buccal film) Phase 2 Elumina trial topline data from 142 TRD patients expected H2'26.","EMP-01 (oral R-MDMA) SAD Phase 2a topline data expected Q1'26; new patent provides exclusivity through 2043.","Redomiciliation to Delaware completed Dec 2025; added to NASDAQ biotech index (NBI) Dec 2025; cash runway into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129166,"accession_number":"0001140361-25-046926","cik":2081043,"company_name":"AtaiBeckley Inc.","ticker":"ATAI","form_type":"8-K12B","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","5.02","3.03","5.03","5.01","5.05","7.01","9.01"],"status":"ready","headline":"AtaiBeckley completes redomiciliation to Delaware; stock continues trading as ATAI on Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redomiciliation from Netherlands to Delaware completed on Dec 30, 2025; approved by ~99% of votes cast.","Each outstanding ordinary share of Atai Beckley N.V. exchanged one-for-one for common stock of AtaiBeckley Inc.","Trading symbol remains ATAI on Nasdaq; new CUSIP 04650F101; Delaware Certificate of Incorporation and Bylaws adopted.","Board and executive officers unchanged; Srinivas Rao remains CEO, Anne Johnson remains CFO.","Company expects cost savings, simplified corporate structure, and streamlined reporting under U.S. incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1614410986.605324,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}